



Fondation du Centre  
Pluridisciplinaire d'Oncologie

## Fondation du Centre Pluridisciplinaire d'Oncologie

CHUV BH 06 - Rue du Bugnon 46 - 1011 Lausanne

### ZOOM EORTC 26053-22054 CATNON

<b>Indication</b>	<b>Des gliomes anaplasiques, OMS Grade III : Astrocytome anaplasique, Oligoastrocytome anaplasique et Oligodendrogliome anaplasique sans perte de translocation chromosomique de 1p/19q</b>
<b>Title</b>	Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.
<b>Protocol ID</b>	<b>EORTC 26053-22054 CATNON</b>
<b>Phase</b>	Phase III
<b>Sponsor</b>	EORTC (European Organisation for Research and Treatment of Cancer)
<b>Local Principal Investigator</b>	Dr R. Stupp
<b>Primary Objective</b>	To assess whether concurrent radiotherapy with daily temozolomide chemotherapy improves overall survival as compared to no daily temozolomide in non-1p/19q deleted anaplastic glioma. To assess whether adjuvant temozolomide chemotherapy improves survival as compared to no adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma
<b>Diagnosis and main criteria for inclusion</b>	Histologically confirmed newly diagnosed anaplastic oligodendroglioma, anaplastic oligoastrocytoma or anaplastic astrocytoma by local diagnosis <b>and</b> absence of combined 1p/19q loss. Availability of tumor material for central 1p/19q assessment, central MGMT promoter methylation assessment and central pathology review. Previous surgery for a low grade tumor is allowed, provided histological confirmation of an anaplastic tumor is present at the time of progression. WHO performance status 0-2. Age $\geq$ 18 years. Start of radiotherapy within 8 days from randomization. Start of radiotherapy within 7 weeks (49 days) from surgery. No prior chemotherapy. No prior radiotherapy to the brain.